The therapeutic vaccines market is anticipated to grow at an annualized rate of more than 50% by 2035, claims Roots Analysis 

Over time, therapeutic vaccines have generated significant interest in the pharmaceutical industry owing to their safety, specificity, augmented immunity and long-term clinical benefits in the treatment of chronic infections and various types of cancer 

Roots Analysis has announced the addition of “Global Therapeutic Vaccines Market, 2022-2035” report to its list of offerings. 

Given that therapeutic vaccines intend to alleviate the suffering of the patient already infected with disease, it is being used as an effective therapy to treat diseases like cancer, HIV and many more prevalent concerns across the globe. It is efficious in treating individuals who are affected with chronic infections but cannot produce enough efficient antibodies.

To order this 350+ page report, which features 90+ figures and 100+ tables, please visit this link

Key Market Insights 

Presently, 350+ therapeutic vaccines have been / are being evaluated across different phases of development for the treatment of various disease indications
Close to 88% of the pipeline candidates are under clinical evaluation and therapeutics, namely Provenge®, Copaxone® and RIAVAX® have been approved for the treatment of prostate cancer, multiple sclerosis and pancreatic cancer respectively. Majority (71%) of these candidates are used for the treatment of oncological disorders, followed by treatment of infectious diseases (9%).

More than 700 clinical trials have been registered for the evaluation of therapeutic vaccines, worldwide 
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 27%, during the period 2019-2021. Of the total number of trials registered, close to 54% have already been completed, while 18% of the studies are actively recruiting participants.

Over 500 grants have been awarded to support the development of therapeutic vaccines, since 2016 
Grants worth USD 467 million have been awarded to various organizations working in this domain during the period, 2016- 2022. Of these, 51% of the grants were awarded to support the research related to projects on therapeutic vaccines, were / are being managed by NIAID, followed by those managed by NCI (30%) and NIDA (4%).

Partnership activity within this domain has increased at a CAGR of 6%, between 2018 and 2020 
More than 35% of the reported deals were established since 2020, with the maximum activity (~50%) being reported in 2020. Majority of the partnerships were product development and commercialization agreements (27%), followed by clinical trial agreements (23%).

Over 20 start-ups have emerged in the last 10 years in the therapeutic vaccines domain 
Over 57% of the start-ups were established in Europe. Among these, more than 25% of the firms are based in France. This is followed by North America, accounting for more than 38% of the start-ups focused on therapeutic vaccines.

North America is anticipated to capture larger share of the market by 2035
In terms of type of vaccine, the major share is captured by dendritic vaccines in the year 2022; this trend is unlikely to change in the foreseen future. Further, among therapeutic areas, vaccines targeting oncological disorders hold the larger market share.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

• Who are the leading industry players involved in developing therapeutic vaccines?
• Which geographies are the most active in conducting clinical trials related to therapeutic vaccines?
• What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
• What are the different initiatives undertaken by start-up players for the development of therapeutic vaccines in the recent past?
• How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the therapeutic vaccines market has been analysed across the following segments:

• Type of Vaccine
  • Antigen Vaccine
  • DNA Vaccine
  • Peptide Vaccine
  • Dendritic Vaccine
• Method of Vaccine Composition 
  • Autologous Vaccine
  • Allogeneic Vaccine 
• Type of Therapy
  • Monotherapy
  • Combination Therapy
• Analysis by Target Disease Indication 
  • Cervical Cancer
  • Ewing Sarcoma
  • Glioblastoma
  • HIV Infection
  • Ovarian Cancer
  • Prostate Cancer
  • Tuberculosis 
• Method of Route of Administration 
  • Intravenous
  • Intradermal
  • Subcutaneous
  • Oral
• Analysis by Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific 
  • MENA
  • Rest of the World

The report includes profiles of key players (listed below) engaged in the development of therapeutic vaccines; each profile features a tabulated overview of company, product portfolio, recent developments, and an informed future outlook.

• BioNTech
• Brii Biosciences
• GlobeImmune
• Immatics
• Immune Response Biopharma
• Immunitor
• Inovio Pharmaceuticals
• Moderna

For additional details, please visit https://www.rootsanalysis.com/reports/global-therapeutic-vaccines-market.html or email sales@rootsanalysis.com 

You may also be interested in the following titles: 

1. RNAi Market, 2022-2035
2. CAR-T Cell Therapies Market, 2022-2035
3. Gene Therapies & Associated Vectors Market, 2022-2035

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com